# US 2026/0015583 A1 · Methods for generating hematopoietic stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0015583 A1
- Document ID: US20260015583A1
- Status: Published application
- Kind: A1
- Application number: 19/088,531
- Filed: 2025-03-24
- Published: 2026-01-15
- Earliest claimed: 2018-06-07
- Assignees: The Brigham and Women S Hospital, Inc.
- Applicants: The Brigham and Women`s Hospital, Inc.
- Inventors: Dhvanit I. Shah
- Web page: https://patentgrep.com/patent/US20260015583A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/28: from vascular endothelial cells
- C12N 2527/00: Culture process characterised by the use of mechanical forces, e.g. strain, vibration
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In some aspects and embodiments, the invention provides methods for making hematopoietic stem cells, including for HSCT. The method comprises providing a cell population comprising hemogenic endothelial (HE) or endothelial cells, and increasing activity or expression of DNA (cytosine-5-)-methyltransferase 3 beta (Dnmt3b) and/or GTPase IMAP Family Member 6 (Gimap6) in the HE and/or endothelial cells under conditions sufficient for stimulating formation of HSCs.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A pharmaceutical composition comprising a cell population comprising long-term hematopoietic stem cells (LT-HSCs), wherein the LT-HSCs reconstitute to multi-lineage adult blood upon transplantation.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein the cell population is derived from induced pluripotent stem cells (iPSCs).

### Claim 31

A pharmaceutical composition comprising a cell population comprising induced pluripotent stem cells (iPSCs) derived hematopoietic stem cells (HSCs), wherein the iPSCs-derived HSCs reconstitute to multi-lineage adult blood upon transplantation.

### Claim 32 (depends on 29)

The pharmaceutical composition of claim 29, wherein the cell population is produced by contacting hemogenic endothelial (HE) cells with a Piezo1 agonist.

### Claim 33 (depends on 32)

The pharmaceutical composition of claim 32, wherein the Piezo1 agonist is Yodal.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, wherein the cell population is HLA-modified.

### Claim 35 (depends on 29)

The pharmaceutical composition of claim 29, wherein the cell population is transgene free.

### Claim 36 (depends on 35)

The pharmaceutical composition of claim 35, wherein the cell population is produced by contacting hemogenic endothelial (HE) cells with a Piezo1 agonist.

### Claim 37 (depends on 36)

The pharmaceutical composition of claim 36, wherein the Piezo1 agonist is Yodal.

### Claim 38 (depends on 37)

The pharmaceutical composition of claim 37, wherein the cell population is HLA-modified.

### Claim 39 (depends on 29)

The pharmaceutical composition of claim 29, wherein the cell population is derived from induced pluripotent stem cells (iPSCs) and transgene free.

### Claim 40 (depends on 39)

The pharmaceutical composition of claim 39, wherein the cell population is produced by contacting hemogenic endothelial (HE) cells with a Piezo1 agonist.

### Claim 41 (depends on 40)

The pharmaceutical composition of claim 40, wherein the Piezo1 agonist is Yodal.

### Claim 42 (depends on 41)

The pharmaceutical composition of claim 41, wherein the cell population is HLA-modified.

### Claim 43 (depends on 29)

A method of treating bone marrow disease in a subject in need thereof, the method comprising:
administering the pharmaceutical composition of claim 29 to the subject by intravenous infusion or intra-bone marrow transplantation.

### Claim 44

A method of transplanting hematopoietic stem cells (HSCs) in a subject in need thereof, the method comprising:
providing a cell population comprising CD34+ cells;
contacting the cell population with an effective amount of a Piezo1 agonist under conditions that form hematopoietic stem cells (HSCs) in the cell population; and then
administering the cell population comprising HSCs to the subject by intravenous infusion or intra-bone marrow transplantation.

### Claim 45 (depends on 44)

The method of claim 44, wherein the providing step comprises:
dissociating at least one embryoid body; and
isolating CD34+ cells.

### Claim 46 (depends on 44)

The method of claim 44, wherein the providing step comprises:
differentiating induced pluripotent stem cells (iPSCs) to form at least one embryoid body;
dissociating the at least one embryoid body into dissociated cells; and
isolating CD34+ cells from the dissociated cells.
